- Home
- FIP vs PRAX Comparison
FIP vs PRAX Comparison
Compare FIP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIP
- PRAX
- Stock Information
- Founded
- FIP 2021
- PRAX 2015
- Country
- FIP United States
- PRAX United States
- Employees
- FIP N/A
- PRAX N/A
- Industry
- FIP Consumer Electronics/Appliances
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FIP Industrials
- PRAX Health Care
- Exchange
- FIP Nasdaq
- PRAX Nasdaq
- Market Cap
- FIP 715.0M
- PRAX 599.7M
- IPO Year
- FIP N/A
- PRAX 2020
- Fundamental
- Price
- FIP $6.58
- PRAX $47.26
- Analyst Decision
- FIP Buy
- PRAX Strong Buy
- Analyst Count
- FIP 1
- PRAX 11
- Target Price
- FIP $12.00
- PRAX $114.73
- AVG Volume (30 Days)
- FIP 1.2M
- PRAX 297.8K
- Earning Date
- FIP 07-31-2025
- PRAX 08-12-2025
- Dividend Yield
- FIP 1.83%
- PRAX N/A
- EPS Growth
- FIP N/A
- PRAX N/A
- EPS
- FIP N/A
- PRAX N/A
- Revenue
- FIP $345,123,000.00
- PRAX $8,122,000.00
- Revenue This Year
- FIP $65.61
- PRAX N/A
- Revenue Next Year
- FIP $30.50
- PRAX $6,358.50
- P/E Ratio
- FIP N/A
- PRAX N/A
- Revenue Growth
- FIP 5.70
- PRAX 270.02
- 52 Week Low
- FIP $3.10
- PRAX $26.70
- 52 Week High
- FIP $10.46
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- FIP 59.51
- PRAX 66.09
- Support Level
- FIP $6.04
- PRAX $40.93
- Resistance Level
- FIP $6.45
- PRAX $44.40
- Average True Range (ATR)
- FIP 0.27
- PRAX 2.24
- MACD
- FIP -0.05
- PRAX 0.11
- Stochastic Oscillator
- FIP 51.25
- PRAX 89.64
About FIP FTAI Infrastructure Inc.
FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.